LianBio American Depositary Shares
LIAN
LIAN was delisted on the 18th of March, 2024.
36 hedge funds and large institutions have $550M invested in LianBio American Depositary Shares in 2021 Q4 according to their latest regulatory filings, with 36 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
83.39% more ownership
Funds ownership: 0% → 83.39% (+83%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$643M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$87.4M |
| 3 |
VA
VR Adviser
New York
|
+$61.4M |
| 4 |
TCM
Tybourne Capital Management
Hong Kong
|
+$37.9M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$36.6M |
Top Sellers
LIAN Hedge Fund Activity: Q4 2021 in Review
36 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in LianBio American Depositary Shares (LIAN) for Q4 2021, worth a combined $550M.
Buyers outnumbered sellers: 36 funds opened new LIAN positions and 0 closed out — a net gain of 36 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $643M.
- 36 institutional investors held LianBio American Depositary Shares (LIAN) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $550M of LianBio American Depositary Shares stock for Q4 2021.
- 36 funds opened new LianBio American Depositary Shares positions in Q4 2021 and 0 closed out, a net change of +36 holders.
- The largest LianBio American Depositary Shares buyer in Q4 2021 was Perceptive Advisors, an estimated $643M added.
Based on aggregated 13F filings for Q4 2021.